Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zomig nasal spray for acute migraine in adolescents
2010-019203-31Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of zolmitriptan in migraine (4 arms), sponsored by AstraZeneca. Primary endpoint: Pain-free status at 2 hours post treatment. Started Sep 2010; status: completed.
02
Drugs
zolmitriptan
03
Conditions
migraine
Beyond the preview
Go deeper on 2010-019203-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019203-31.